Lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate (LPA)) is a phospholipid with diverse biological activities. The mediator serves as an intermediate in membrane phospholipid metabolism but is also produced in acute settings by activated platelets. LPA is converted to phosphatidic acid, itself a lipid mediator, by an LPA acyltransferase (LPAAT). A human expressed sequence tag was identified by homology with a coconut LPAAT and used to isolate a full-length human cDNA from a heart muscle library. The predicted amino acid sequence bears 33% identity with a Caenorhabditis elegans LPAAT homologue and 23-28% identity with plant and prokaryotic LPAATs. Recombinant protein produced in COS 7 cells exhibited LPAAT activity with a preference for LPA as the acceptor phosphoglycerol and arachidonyl coenzyme A as the acyl donor. Northern blotting demonstrated that the mRNA is expressed in most human tissues including a panel of brain subregions; expression is highest in liver and pancreas and lowest in placenta. The human LPAAT gene is contained on six exons that map to chromosome 9, region q34.3.
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Lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate (LPA)) 1 is a potent bioactive lipid with diverse biological activities that range from the physiologic to the pathophysiologic. Natural physiologic functions include mitogenesis, cell differentiation, platelet aggregation, actin cytoskeleton remodeling, monocyte chemotaxis, smooth muscle contraction, and neurite retraction (1) . In vitro experiments suggest that LPA can also impact immune cell functions such as proliferation and IL-2 production (2) . The phospholipid may also participate in the pathophysiology of neurodegenerative processes by causing vasoconstriction as well as impairment of glutamate and glucose uptake by astrocytes (3, 4) . In addition, LPA is a potent promoter of tumor cell growth and invasion (5, 6) . LPA exerts its biological effects via at least one, but perhaps multiple, specific G protein-coupled receptors (7) (8) (9) . Engagement of the receptor results in activation of Ras and the Raf/mitogen-activated protein kinase pathway, stimulation of phospholipases C and D, inhibition of adenylyl cyclase, and tyrosine phosphorylation of focal adhesion proteins along with actin cytoskeleton remodeling (1) .
Given the breadth of its biological impact, LPA metabolism has been a subject of intense study. During membrane phospholipid biosynthesis, LPA is formed by acylation of sn-glycerol-3-phosphate or by acylation of dihydroxyacetone phosphate followed by reduction of the acyl-dihydroxyacetone phosphate (10) . In contrast, LPA that is rapidly generated in the plasma membrane of thrombin-activated platelets and growth factorstimulated fibroblasts (11, 12) appears to arise from hydrolysis of phosphatidic acid (PA) by a phospholipase A 2 (13) (14) (15) . Additionally, Fourcade et al. (16) have demonstrated that a secretory phospholipase A 2 acts upon membrane microvesicles shed from activated cells to convert PA to LPA. PA is a key intermediate in membrane phospholipid biosynthesis (10) , but it can also serve as a second messenger in activated cells (17) . PA can be converted to CDP-diacylglycerol or to diacylglycerol by the action of PA phosphatase or to LPA by the phospholipase A 2 .
LPA is present in serum at physiologically active concentrations. Because activated platelets copiously secrete the mediator, it has been suggested that aggregated platelets are the primary source of the serum LPA (14, 18) . This source, coupled with the mitogenic and chemotactic properties of LPA, has prompted the hypothesis that the phospholipid is an important mediator of wound healing (12) . Additionally, several of the known effects of LPA are consistent with a potential proinflammatory or proimmune function. The fact that the phospholipid is present in serum at functional concentrations implies the necessary presence of an "anti-LPA" mechanism to preclude inappropriate activation of LPA-sensitive cells. Consistent with this, there appear to be at least three mechanisms whereby LPA bioactivity might be attenuated. (i) LPA can be converted to PA in cells by the action of LPA acyltransferase (LPAAT) (7, 10) . This enzyme is found in microsomes and the plasma membrane (29) and may be regulated by phosphorylation in response to interleukin-1 (IL-1) (29, 34) . (ii) An ecto-(lyso) PA phosphatase can generate mono-or diacylglycerol from LPA or PA with a short sn-2 acyl chain (19) . (iii) An LPA-specific lysophospholipase activity has been purified from rat brain (20) .
Genetic and molecular biological approaches have facilitated cloning of genes encoding the LPAAT from nonmammalian species; however, no cloning of the mammalian counterparts of any of the key regulatory proteins has been reported. In plants, storage triacylglycerols are synthesized via a four-step pathway that involves acylation of glycerol 3-phosphate at the sn-1 position to form LPA, acylation of LPA by LPAAT, and then conversion of the PA to diacylglycerol by PA phosphatase followed by sn-3 acylation to form triacylglycerol (21) . Interest in this metabolic pathway from the perspective of understanding and manipulating plant oil production has resulted in the cloning of several plant cDNAs that encode enzymes with LPAAT activity (22) (23) (24) (25) . Interestingly, these cDNAs have extensive * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The sequence homology with each other as well as with LPAAT cDNAs from prokaryotic organisms, yeast, and nematodes. This prompted us to explore the Expressed Sequence Tag (EST) data base for uncharacterized mammalian homologues of the plant and microbial LPAATs. In this report we describe the EST-based cloning of a human LPAAT cDNA. The enzyme preferentially acylates LPA with arachidonate and is expressed in most tissues.
EXPERIMENTAL PROCEDURES
Genomic DNA and cDNA Cloning-A TBLASTN search of the GenBank TM dbest data base using the coconut LPAAT sequence (25) identified two human ESTs deposited by the WashU-Merck EST project with accession numbers H39628 and H44282. Based upon the EST sequences, two oligonucleotide primers (forward: 5Ј-GGGCCTCATCA-TGTACCTCGGGGGCG-3Ј; reverse: 5Ј-CTGCCCTCCCCCAGGTC-3Ј) were designed and used in a polymerase chain reaction (PCR) to obtain a fragment of the LPAAT homologue cDNA from a human macrophage cDNA library (26) . The fragment was used to generate a radiolabeled probe by random priming (Random Primed Labeling Kit, Boehringer Mannheim) that was applied to both a human heart muscle cDNA library in Lambda Zap II and a genomic DNA library in Lambda Fix II (both from Stratagene, La Jolla, CA). Approximately 5 ϫ 10 5 to 1 ϫ 10 6 phage were blotted onto nitrocellulose and screened in 50% formamide, 0.75 M sodium chloride, 75 mM sodium citrate, 50 mM sodium phosphate (pH 6.5), 1% polyvinylpyrrolidine, 1% Ficoll, 1% bovine serum albumin (BSA), and 100 g/ml sonicated salmon sperm DNA. After overnight hybridization at 42°C, blots were washed extensively in 3 mM sodium chloride, 0.3 mM sodium citrate, 0.1% SDS at 50°C. Following a secondary screen under identical conditions, individual hybridizing plaques were selected for DNA purification. The nucleotide sequence of both strands of the cDNA was determined. Genomic DNA was excised from the Lambda Fix II vector by NotI digestion and subcloned into pBluescript (Stratagene). Genomic organization was determined by nucleotide sequencing of the genomic clone with oligonucleotide primers based upon the cDNA sequence. Additional primers designed according to intron sequence were used to sequence across the exon/intron boundaries and through the exons. Sequencing was accomplished by the automated dideoxy chain termination method. Expression of Recombinant Enzyme-An expression construct was engineered to contain the LPAAT coding region flanked at the 3Ј end by a sequence encoding the FLAG tag (Eastman Kodak Co., Rochester, NY; 5Ј-GACTACAAGGACGACGATGACAAG) to facilitate detection of recombinant protein. Oligonucleotide primers located 53 base pairs upstream of the LPAAT cDNA translation initiation codon (Start R1: 5Ј-ATCAGAATTCCGGGAGCGGGAGCGGGAGCGAGCTGGCGGCGC) and at the termination codon (FLAG Stop Xba: 5Ј-ATTCTCTAGACTA-CTTGTCATCGTCGTCCTTGTAGTCCTGGGCCGGCTGCACGCCAG-A-CCCCGCAGTGGCCCCGTTC) were synthesized and used to generate a PCR fragment that could be digested with EcoRI and XbaI. The digested fragment was cloned into the corresponding restriction sites of the eukaryotic expression vector, pcDNA3 (Invitrogen, Carlsbad, CA). The nucleotide sequence of the expression construct insert was determined to ensure that no sequence changes were introduced by the PCR. COS 7 cells were seeded at a density of 600,000 per 60-mm tissue culture dish in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 1 mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin. The following day the cells were transfected in Dulbecco's modified Eagle's medium containing 0.5 mg/ml DEAE-dextran, 0.1 mM chloroquine, and 10 g of plasmid DNA for 1.5 h. The cells then were treated with 10% Me 2 SO in phosphate-buffered saline for 45 s, washed with serum-free medium, and incubated in Dulbecco's modified Eagle's medium supplemented with 1 mM L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, and 10% fetal calf serum. After 4 days, the medium was removed, and cells were rinsed twice with phosphate-buffered saline and harvested by scraping in 0.2 ml of 20 mM Tris-HCl, pH 7.5, and 5 mM NaCl. Cells were lysed by sonication. Mock-transfected cells served as a negative control.
Determination of LPAAT Activity-COS 7 cell lysates containing recombinant LPAAT were assayed for acyltransferase activity with various combinations of acyl donors and acceptors. Donors included myristoyl coenzyme A, palmitoyl coenzyme A, stearoyl coenzyme A, and arachidonyl coenzyme A (all from Sigma). Acyl acceptors tested included 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphate, 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine, 1-alkyl-2-hydroxy-sn-glycero-3-phosphocholine (all from Avanti Polar Lipids, Alabaster, AL). Each assay contained 10 l of cell lysate diluted 10-fold added to 240 l of assay buffer and substrate. Final concentrations of assay components are as follows: 100 mM HEPES-NaOH (pH 7.5), 200 mM NaCl, 5% (w/v) glycerol, 10 mM EDTA, and 5 mM ␤-mercaptoethanol. Acyl acceptor species were added to a final concentration of 20 M. Also included was 1.3 M 14 C-radiolabeled acyl-CoA donor substrate (American Radiolabeled Chemicals, St. Louis, MO) and 40 M of the corresponding nonlabeled acyl-CoA. After a 5-min incubation at 37°C, reactions were terminated by the addition of 250 l of 1 M KCl, 0.2 M H 3 PO 4 , and 40 l of 1 mg/ml BSA. Lipids were extracted by the addition of 0.75 ml of chloroform:methanol (2:1). The resulting organic phase was recovered, and 400 l was dried to 30 l and applied to a silica gel thin layer chromatography plate (TLC; 0.25-mm layer). Ascending TLC was performed in chloroform: pyridine:formic acid (50:30:7). Radioactive spots resolved by TLC were quantitated using a PhosphoImager with ImageQuant 3.0 software (Molecular Dynamics, Sunnyvale, CA). The authenticity of the labeled product as PA was confirmed by comigration with PA in the TLC system; in addition, PA was not produced in the absence of LPA. The amount of PA generated was expressed as phosphoimaging units/g of protein.
All assays were conducted in triplicate.
Western Blotting-Proteins from COS 7 cell lysates were separated by SDS-polyacrylamide gel electrophoresis (12% gel; Novex, San Diego, CA) and electrotransferred to a polyvinylidene fluoride membrane (Pierce) for 1 h at 125 V in 192 mM glycine, 25 mM Tris base, 20% methanol, and 0.01% SDS. The membrane was incubated in 20 mM Tris, 100 mM NaCl (TBS) containing 5% BSA overnight at 4°C. The blot was subsequently incubated 1 h at room temperature with 1 g/ml of an anti-FLAG antibody (Kodak) in TBS containing 5% BSA, then washed with TBS, and incubated with a horseradish peroxidase-conjugated goat anti-mouse IgG in TBS containing 5% BSA for 1 h at room temperature. The blot was again washed with TBS and the signal was developed by electrochemiluminescence (NEN Life Science Products) according to the supplier's protocol.
Tissue mRNA Expression Analysis-Northern blots containing poly(A)-selected human RNA from various tissues were obtained from CLONTECH (Palo Alto, CA). The blots were prehybridized for 6 h at 42°C in 50% formamide, 0.75 M sodium chloride, 75 mM sodium citrate, 50 mM sodium phosphate (pH 6.5), 1% polyvinylpyrrolidine, 1% Ficoll, 1% BSA, 2% SDS, and 100 g/ml sonicated salmon sperm DNA. After overnight hybridization in the same solution containing 1 ϫ 10 6 dpm/ml 32 P-labeled LPAAT coding region DNA, blots were washed extensively in 30 mM sodium chloride, 3 mM sodium citrate, 0.1% SDS at 50°C and exposed to film overnight.
Chromosomal Localization-A 20-kilobase genomic fragment containing the LPAAT gene was labeled with digoxigenin by nick translation and used as a probe for fluorescence in situ hybridization (FISH) of human chromosomes (Genome Systems, Inc., St. Louis, MO). The labeled probe was hybridized to normal metaphase chromosomes derived from phytohemagglutinin-stimulated peripheral blood lymphocytes. Reactions were carried out in the presence of sheared human DNA in 50% formamide, 10% dextran sulfate, 30 mM sodium chloride, 3 mM sodium citrate, 0.1% SDS. Hybridization signals were detected by treating slides with fluoresceinated antidigoxigenin antibodies followed by counterstaining with 4,6-diamidino-2-phenylindole. Initial labeling implicated a group C chromosome. A p16 INK4A probe that specifically hybridizes to chromosome 9, band p21 was used to demonstrate cohybridization of chromosome 9 with the LPAAT probe. A total of 80 metaphase cells were analyzed with 45 exhibiting specific labeling.
Sequence and Genetic Data Analysis-Nucleotide sequences were analyzed with Geneworks (IntelliGenetics, Mt. View, CA). Amino acid sequence alignments were conducted using the ClustalW1 algorithm as found in the BCM Search Launcher-Multiple Sequence Alignments (http://dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.html). Individual pairwise alignments were conducted using Align Query (http: //vega.crbm.cnrs-mop.fr/bin/align-guess.cgi). 
RESULTS
Identification of LPAAT cDNA-The coconut LPAAT cDNA sequence (25) was used to conduct a TBLASTN search of the GenBank TM EST data base for mammalian homologues. Five ESTs derived from human tissue cDNA libraries displayed significant sequence homology with the plant sequence. The sequences of two of these (accession numbers H39628 and H44282) were used to generate PCR primers for screening a human macrophage cDNA plasmid library (26) . A partial macrophage cDNA was used to screen a human heart muscle cDNA library for additional clones. The nucleotide sequence of a hybridizing heart clone contains an open reading frame predicted to encode a polypeptide of 278 amino acids with a molecular mass of 30.9 kDa (Fig. 1A) . The predicted protein sequence exhibits 23.2% identity with the coconut LPAAT, but its identity with other members of the LPAAT family ranges as high as 33% (Table I) . Like the other LPAATs, the human enzyme is predicted to have multiple hydrophobic regions which may serve as transmembrane domains (Fig. 1B) . While complete sequence identity at any given amino acid position between all members of the family is relatively infrequent, a core region of highly conserved amino acids is found from positions 167-205 of the human sequence (Fig. 2) .
Enzymatic Activity of Recombinant LPAAT-We subcloned 
TABLE I Percent amino acid identity of LPAAT between human
and other species C. elegans, H. influenza, and S. typhimurium sequences are predicted LPAATs based on sequence homology with known LPAATs (see Fig. 2 Fig. 3 , transfected cells exhibited 17-fold greater LPAAT activity than the mock-transfected cells when arachidonyl coenzyme A was used as substrate. Under the conditions of the assay, acyl chain transfer tended to be reduced with the shorter, saturated acyl substrates when comparing transfected cells with the corresponding mock-transfected controls (6-to 10-fold increase in PA formation). The enzyme was unable to utilize lysophosphatidylcholine as the acyl chain acceptor. mRNA Tissue Expression Patterns-Northern blot analyses demonstrated that the human LPAAT mRNA is differentially expressed (Fig. 4) . Highest expression was seen in the liver and pancreas; particularly low levels were found in a section of brain and in placental tissue. Low expression in the brain was unexpected since the LPA receptor is expressed at high levels in neural tissue (8) . To determine if regional localization might account for this result, we hybridized a Northern blot containing multiple brain subregions with the human LPAAT cDNA. While the message was found in every region represented on the blot, expression was greater in the spinal cord and subthalamic nucleus and least in the cerebellum, caudate nucleus, corpus callosum, and hippocampus (Fig. 4B) . Northern blot analysis of LPAAT expression in the human myeloid-like cell lines THP-1, HL-60, and U937 suggested that the gene is constitutively expressed in these cells. Treatment of any of these cell lines with phorbol 12-myristate 13-acetate or treatment of HL-60 cells with Me 2 SO had no effect on message levels (not shown).
Genomic Structure and Organization-We examined a human genomic DNA library and found that the entire LPAAT gene consists of six exons (Table II) , all of which are located on a single 20-kb genomic clone. Exon 1 contains 66 bp of 5Ј-noncoding sequence and encodes the first 61 amino acids of the predicted polypeptide. The average size of the exons, exclusive of exon 6, is 145 nucleotides. Exon 6 is much larger (784 nucleotides) and contains all of the 3Ј-untranslated sequence as well as sequence encoding the 58 most C-terminal amino acids. With the exception of the splice donor sequence of the intron 3Ј of exon 1, all splice junctions agree favorably with the known consensus splice sites for mammalian genes (28) .
Chromosomal Localization-To establish the chromosomal location of the human LPAAT gene, FISH analysis was performed using the 20-kb human genomic clone as a probe. An initial hybridization experiment localized the gene to the q terminus of a group C chromosome. Subsequent cohybridization experiments with a p16 INK4A probe implicated the q terminus of chromosome 9. Further evaluation of 10 specifically hybridized chromosomes pinpointed the location of the LPAAT gene to band 9q34.3 (Fig. 5) .
The LPAAT gene shares the 9q34.3 address with numerous genes of varied functions. These include a number of enzymes such as the fucosyltransferase gene, FUT7, the dopamine-␤-hydroxylase gene, as well as the lipid-metabolizing enzymes carboxyl ester lipase and prostaglandin D2 synthase. Genes encoding receptors include the N-methyl-D-aspartate receptor 1 and the retinoid X receptor. Diseases associated with this region include type II Ehlers-Danlos syndrome, which arises from a collagen V translocation, and a T-cell acute lymphoblas- toid leukemia associated with a Notch homologue 1 translocation. Guanine nucleotide-releasing factor 2, orosomucoid 1 and 2 glycoproteins, and the homeodomain protein LHX3 also map to this region. There are no obvious functional relationships between the LPAAT and other gene products or associated diseases that map to the 9q34.3 location.
DISCUSSION
This manuscript describes the first cloning of a mammalian LPAAT cDNA. The significant homology with LPAATs from organisms as diverse as plants, nematodes, and prokaryotes supports our observations that the enzyme catalyzes the conversion of LPA to PA. The enzyme appears to be expressed in most tissues, suggesting it is an essential component of phospholipid metabolic pathways. The enzyme may also participate in intracellular signaling by generating PA, a known second messenger, or by regulating levels of LPA.
The predicted amino acid sequence of the human LPAAT is homologous to other LPAATs and thus displays a very similar hydropathy profile. Analysis of the human sequence for potential transmembrane domains strongly predicted four transmembrane helices (Fig. 1B) . The first putative transmembrane domain may in fact represent a signal peptide (residues 1-23). However, the very short hydrophilic sequence between this putative signal peptide and the following hydrophobic helix is unusual, perhaps supporting a role for the first hydrophobic region being an integral transmembrane domain. The TMpred algorithm predicts the first (residues 3-21) and third (residues 123-141) putative transmembrane helices to be oriented within the membrane outside to inside and the second (residues 30 -50) and fourth (residues 189 -207) helices to be oriented inside to outside. This orientation places the predicted N-glycosylation site (Asn-59) and O-glycosylation sites (Thr-233, Thr-262) outside of the membrane. Interestingly, one of the predicted protein kinase phosphorylation sites (Thr-174) orients internal to the membrane in this configuration. This threonine lies within the most highly conserved region of the protein and is itself completely conserved in the eight most closely related members of the LPAAT family (Fig. 2) . These observations, while speculative, are consistent with an integral plasma membrane localization of the enzyme such as has been proposed (29) . Similarly, the PA metabolizing enzyme, PA phosphatase 2, is predicted to have five or six transmembrane domains and is thought to localize to the plasma membrane (30) . It will be of interest to examine the spatial relationship between the two enzymes; perhaps they comprise part of a multienzyme locus that mediates LPA/PA metabolism.
Northern blot analysis (Fig. 4) demonstrated that the LPAAT message is expressed at very high levels in the liver and pancreas, at low levels in the placenta and certain regions of the brain, and at intermediate levels in numerous other tissues. This pattern of expression is in marked contrast to the pattern seen with the LPA receptor, which is expressed most abundantly in the brain, not in the liver, and at intermediate levels in other tissues (7, 8) . This suggests the possibility that, at least in the brain and liver, LPA signaling and metabolism are mediated by additional receptors and enzymes. The cloning from Xenopus oocytes of an LPA receptor cDNA that bears little sequence identity to the mouse brain LPA receptor supports this possibility (9) .
It is not clear if the LPAAT described in this report has a significant role in modulating the intercellular signaling function of the LPA produced by activated cells or if it primarily serves to generate the PA intermediate in the membrane phospholipid synthetic pathway. The apparent constitutive and widespread LPAAT mRNA expression patterns may support the latter possibility. Further support is derived from experiments in which quiescent fibroblasts degraded exogenous LPA primarily to monoacylglycerol (31) , suggesting that the LPA was catabolized by a phosphatase rather than acylated by an LPAAT. On the other hand, stimuli such as IL-1␤, tumor necrosis factor-␣, platelet-activating factor, and lipid A stimulate rapid accumulation of intracellular PA (29, 32, 33) . This appears to occur as a result of phosphorylation-mediated activation of an intracellular pool of LPAAT (34) . It is also possible that expression of the LPAAT message is up-regulated in response to specific stimuli or in cell types not examined in the current study.
The biological consequences that arise from metabolic processing of acutely generated LPA remain ambiguous. LPA at the site of inflammation or tissue injury may mediate wound healing but, in local or temporal excess, may participate in propagating an inflammatory response. In this situation, there must be a mechanism to resolve the effects of the mediator. One possible mechanism is to catabolize LPA via a phosphatase or lysophospholipase to produce a simple glycerolipid that is subject to rapid recycling. In contrast, the product of LPA acylation is PA. A number of recent reports have suggested that PA may be a key intracellular messenger in a common signaling pathway activated by proinflammatory mediators such as IL-1␤, tumor necrosis factor-␣, platelet-activating factor, and lipid A (29, 32, 33) . That this PA is generated by the action of LPAAT was demonstrated by the observation that small molecule inhibitors of the enzyme block PA formation in P388 monocytic leukemia cells stimulated with bacterial lipopolysaccharide (35) and in hypoxia-treated human neutrophils (36) . The small molecule inhibitors also protected mice from lipopolysaccharide-mediated endotoxic shock and from lung injury in a model of hemorrhage and resuscitation (36) . Others have demonstrated that formyl peptide-stimulated neutrophils can be induced to produce PA by a phospholipase D-dependent mechanism (17) . In this setting, the PA activated NADPH oxidase. In these examples, PA generated intracellularly in response to a particular extracellular stimulus mediates signaling. Many reports implicate PA as an extracellular agonist as well. The phospholipid purportedly stimulates monocyte migration (37) , is mitogenic to Balb-c/3T3 cells (11) , causes superoxide generation in neutrophils, activates protein phosphorylation, and stimulates phosphatidylinositol-4-phosphate kinase, and inactivates Ras GTPase-activating protein (reviewed in Ref. 38) . It has been suggested, however, that contaminating LPA may be the mediator of at least some of these effects (39) . All of these observations suggest that PA is an important signaling molecule, at least intracellularly. Whether generation of PA via acylation of LPA in the extracellular milieu at an inflammatory site leads to further cellular activation remains to be determined experimentally. 
FIG. 5. Localization of human LPAAT to chromosome 9.
A, FISH analysis of human metaphase chromosomes marks band 34.3 of the q arm of chromosome 9. Faint spots on the opposite terminus of the chromosome (9p arm) are due to hybridization of the chromosome 9 marker, p16 INK4A. B, arrow illustrates on the idiogram the position at which the LPAAT genomic probe hybridizes to chromosome 9.
